@misc{Dulak_Józef_Gene_2004,
 author={Dulak, Józef and Józkowicz, Alicja},
 volume={66},
 number={3},
 copyright={Creative Commons Attribution BY-SA 4.0 license},
 journal={Biotechnologia, vol.66, 3 (2004)-.},
 howpublished={online},
 year={2004},
 publisher={Committee on Biotechnology PAS},
 publisher={Institute of Bioorganic Chemistry PAS},
 language={pol},
 abstract={Despite progress in pharmacotherapy, there is still a lack of efficient treatment of advanced stages of cardiovascular diseases. Therefore, great expectations are connected with gene therapy. First clinical experiments of gene transfer of vascular endothelial growth factor (VEGF) were carried out in 1994-1998 on patients with critical leg ischemia. They resulted in the improvement of vascularisation and prevented the amputation of the limbs. Promising results have been also obtained with DNA decoys binding the EF2 transcription factor. In this way, the expression of genes enhancing the proliferation of vascular smooth muscle cells have been inhibited and in consequence the narrowing of the lumen of arterio-venous bypasses have been inhibited.},
 title={Gene therapy of cardiovascular diseases},
 type={Text},
 URL={http://www.rcin.org.pl/Content/113846/PDF/POZN271_142172_biotechnologia-2004-no3-dulak.pdf},
 keywords={biotechnology},
}